小智港股覆盤 | 10月13日
今日，港股三大指數集體下跌。截止收盤，恆生指數跌1.87%，報16389點。國企指數大跌2.31%，報5560點。恆生科技指數大跌3.42%，報3157點。市場約540只個股上漲，1082只個股下跌。成交額突破849.92億港幣，和昨天同期相比下跌24.65%。南下資金淨流入50.14億港幣。
盤面上，生物科技板塊集體拉昇。百濟神州漲超14%；榮昌生物-B漲超6%；東曜藥業-B、君實生物等多股漲超4%；聯康生物科技集團漲超3%。醫藥板塊集體走強，百濟神州漲16.47%，機構料醫藥多板塊觸底時刻已經到來；榮昌生物-B升6%，泰它西普治療重症肌無力(MG)獲FDA“孤兒藥”，認定；君實生物升6%，特瑞普利聯合治療NSCLC最新III期研究成果發佈，已在國內獲批六項適應症。
電力板塊跟隨走強。協鑫新能源漲超8%；華能國際電力股份、大唐新能源、普星能量等多股漲超6%；華電國際電力股份漲超5%。部分光伏太陽能股走強，協鑫新能源漲10.81%；華能國際電力股份漲3.09%，獲上海睿郡資產管理有限公司增持70萬股H股；大唐新能源：“21唐新Y3”將於10月13日兌付本息，發行總額人民幣10億元。
包裝印刷板塊活躍。嘉耀控股漲超7%；中糧包裝、錦勝集團(控股)等多股漲超3%；萬成集團股份、TEAMWAY INTL GP等多股漲超2%。
互聯網醫療板塊暴跌。醫脈通跌超14%；阿裏健康跌超8%；中智全球跌超5%；醫渡科技跌超3%；平安好醫生跌超2%。醫渡科技授出1,837萬份購股權。
商業服務板塊全線走低。長城匯理跌超29%；信能低碳跌超17%；瑩嵐集團、旭輝永升服務等多股跌超15%；碧桂園服務跌超14%。旭輝永升服務：繼續向旭輝集團提供物業管理服務至2025年；匯豐研究下調碧桂園評級至「減持」，碧服降級至「持有」。
建築建材板塊全線走低。中國宏光、中國聯塑等多股跌超7%；中國玻璃跌超5%；中國建築興業跌超1%。中國玻璃獲高管增持合共861.2萬股。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
